Impact ledger
Illumina, Inc. (ILMN): the developments shaping its investment case
Follow the evidence affecting Illumina, Inc.'s financing assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Illumina, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-21
Magnetic Bead Purification Market Forecast to Expand at 10.5% CAGR to $6.73B by 2030
Channel: Increased demand for sample preparation solutions, including magnetic beads, as a precursor to genomics sequencing workflows.
Bullish· 1-5y
2026-08-17
Illumina, Inc. Prices $300 Million 4.950% Notes due 2029
Channel: Direct impact on capital structure and financing costs. Potential use of proceeds for strategic initiatives or debt refinancing.
mixed· 1-3m
2026-09-27 · 2 reports
Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm
Channel: Accelerated drug discovery and biotechnology research, potentially increasing demand for genomic sequencing and related data analysis tools.
Bullish· 3-12m
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-12 | wacc | Bearish | IG cost of debt is below blended cost of capital; weighting effect lowers WACC. |
| 2026-08-12 | interest_expense | Bullish | New IG coupon adds to recurring interest expense. |
| 2026-08-12 | net_debt | Bullish | Investment-grade issuance adds gross debt to the balance sheet. |
| 2026-06-23 | net_debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. |
| 2026-06-23 | interest_expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. |
Event impact log
10 events mapped to ILMN since 2026-08-17. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | Quantum-Si Interim Proteus Data Shows 30x Alignment Gain Over Platinum Pro | Increased competitive pressure in the broader life sciences tools and diagnostics market, particularly in proteomics. | watch | 3-12m | 0.30 |
| 2026-09-27 | Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm | Accelerated drug discovery and biotechnology research, potentially increasing demand for genomic sequencing and related data analysis tools. | Bullish | 3-12m | 0.40 |
| 2026-09-27 | Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize | Advancements in open-source AI for therapeutic design and peptide research could accelerate drug discovery and development, potentially increasing demand for genomic sequencing and analysis tools, which Illumina provides. | Bullish | 1-3m | 0.40 |
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Increased demand for genomic sequencing and synthetic biology tools and consumables as the sector grows and secures more funding. | Bullish | 3-12m | 0.20 |
| 2026-09-25 | Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant Discovery | While AI-driven drug discovery could increase demand for genomic sequencing (Illumina's core business), it also represents a shift towards computational methods that might reduce reliance on traditional lab workflows, potentially impacting some aspects of their business model or creating new competi | mixed | 1-5y | 0.40 |
| 2026-09-21 | Magnetic Bead Purification Market Forecast to Expand at 10.5% CAGR to $6.73B by 2030 | Increased demand for sample preparation solutions, including magnetic beads, as a precursor to genomics sequencing workflows. | Bullish | 1-5y | 0.50 |
| 2026-09-20 | Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal | Broader industry trend towards AI-driven drug discovery leveraging genomic data, potential for increased demand for sequencing. | watch | 3-12m | 0.20 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Increased demand for genomic sequencing and related tools as gene therapy development and commercialization expands. | Bullish | 3-12m | 0.20 |
| 2026-08-31 | Tempus AI, Inc. to Acquire Personalis, Inc. in All-Stock Transaction | Second-order M&A impact: Increased competition/consolidation in genomics/AI diagnostics market. | watch | 3-12m | 0.30 |
| 2026-08-17 | Illumina, Inc. Prices $300 Million 4.950% Notes due 2029 | Direct impact on capital structure and financing costs. Potential use of proceeds for strategic initiatives or debt refinancing. | mixed | 1-3m | 0.40 |
Continue this research
Build your Illumina, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the ILMN entity page →